NRT and lung cancer?
This article was originally published in The Tan Sheet
Executive Summary
It is "a possibility that exposure to nicotine, by smoking or through nicotine supplements, might negatively impact the response to chemotherapeutic agents," Piyali Dasgupta, H. Lee Moffitt Cancer Research Center, Tampa, FL, et al., report at the American Association for Cancer Research annual meeting in Washington, D.C. April 2. Although nicotine is not a carcinogen, "it can induce cell proliferation" and suppress the killing of cancer cells induced by certain agents, the authors note. Their study finds that administering nicotine (1 µm) inhibited treatments for non-small cell lung cancer, such as gemcitabine, cisplatin and taxol...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.